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Abstract
Background: Cancer vaccines are designed to activate and enhance cancer-antigen-targeted T cells that are suppressed
through multiple mechanisms of immune tolerance in cancer-bearing hosts. T regulatory cell (Treg) suppression of tumor-
specific T cells is one barrier to effective immunization. A second mechanism is the deletion of high avidity tumor-specific T
cells, which leaves a less effective low avidity tumor specific T cell repertoire available for activation by vaccines. Treg
depleting agents including low dose cyclophosphamide (Cy) and antibodies that deplete CD25-expressing Tregs have been
used with limited success to enhance the potency of tumor-specific vaccines. In addition, few studies have evaluated
mechanisms that activate low avidity cancer antigen-specific T cells. Therefore, we developed high and low avidity HER-2/
neu-specific TCR transgenic mouse colonies specific for the same HER-2/neu epitope to define the tolerance mechanisms
that specifically affect high versus low avidity tumor-specific T cells.
Methodology/Principal Findings: High and low avidity CD8
+ T cell receptor (TCR) transgenic mice specific for the breast
cancer antigen HER-2/neu (neu) were developed to provide a purified source of naı ¨ve, tumor-specific T cells that can be
used to study tolerance mechanisms. Adoptive transfer studies into tolerant FVB/N-derived HER-2/neu transgenic (neu-N)
mice demonstrated that high avidity, but not low avidity, neu-specific T cells are inhibited by Tregs as the dominant
tolerizing mechanism. High avidity T cells persisted, produced IFNc, trafficked into tumors, and lysed tumors after adoptive
transfer into mice treated with a neu-specific vaccine and low dose Cy to deplete Tregs. Analysis of Treg subsets revealed a
Cy-sensitive CD4
+Foxp3
+CD25
low tumor-seeking migratory phenotype, characteristic of effector/memory Tregs, and capable
of high avidity T cell suppression.
Conclusion/Significance: Depletion of CD25
low Tregs allows activation of tumor-clearing high avidity T cells. Thus, the
development of agents that specifically deplete Treg subsets should translate into more effective immunotherapies while
avoiding autoimmunity.
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Introduction
Activation, amplification, and survival of CD8
+ cytotoxic T
lymphocytes (CTL) are required as part of a successful adaptive
immune response to developing tumors. High avidity antigen-
targeted CTL can exit the thymus after selection, even though
many recognize altered self-proteins. However, multiple mecha-
nisms of peripheral immune tolerance exist that prevent complete
activation of CTL, including ignorance, deletion, functional
inactivation, and T regulatory cell (Treg)-mediated suppression
[1,2,3,4,5,6]. Low avidity CTL specific for the same antigenic
epitope easily exit the thymus but are thought to remain non-
functional in the periphery, presumably due to inefficient
activation and maintenance of function. Due to efficient thymic
deletion and peripheral suppression of high avidity T cells, low
avidity T cells are the predominant population of T cells available
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31962for activation in the periphery of cancer bearing hosts. Therefore,
model systems allowing tracking and the dissection of mechanisms
of regulation of sub-populations of antigen-targeted CTL are
needed to decipher barriers to CTL clearance of tumors in cancer
bearing hosts.
Suppression by Tregs is one well-described tolerance mecha-
nism. Tregs inhibit the activation and recruitment of antigen-
targeted CTL. It is unclear whether Tregs suppress both high and
low avidity antigen-targeted CTL, and how and where this
suppression occurs in tumor-bearing hosts. Understanding the
mechanism by which Tregs suppress these CTL is complicated by
the recent discovery of Treg subsets that may be more potent
suppressors of CTL, and may traffic more efficiently to areas of
inflammation. Effector/memory-like CD4
+Foxp3
+ Tregs have
been described that preferentially migrate to non-lymphoid and
inflamed tissues to exert suppressive effects [7,8]. These studies
suggest that Tregs represent a heterogeneous population of cells
responsible for a variety of suppressive and migratory functions.
Therefore, it is critical to understand which Treg populations
provide cancer-antigen-targeted CTL suppression within tumors
so that agents can be identified to effectively suppress these sub-
populations as part of immune activating therapies. The
availability of naı ¨ve purified T cells with defined avidities that
are specific for a cancer-targeted antigen allows for the dissection
of the mechanisms involved in suppression, activation, and
trafficking of antigen-targeted CTL in tolerant tumor-bearing
hosts.
We previously demonstrated that FVB/N mice produce an
oligoclonal high avidity T cell response against the immunodomi-
nant neu-derived CD8
+ T cell epitope, RNEU420–429,w h e n
vaccinated with a neu and granulocyte-macrophage colony-
stimulating factor (GM-CSF)-expressing whole cell vaccine. How-
ever, this same vaccine induces only low avidity RNEU420–429-
specificT cellsinneu-Nmicethat arenaturallytoleranttoneu dueto
the expression of the neu transgene in mammary tissue [9,10]. We
previously reported that 20–30% of neu-N mice treated with this
vaccine andimmunemodulatingdosesofcyclophosphamide(Cy) to
deplete Tregs develop high avidity RNEU420–429-specific CTL
responses that are associated with tumor clearance. In contrast,
mice developing only low avidity RNEU420–429-specific CTL fail to
clear tumor [11]. These findings suggest that one difference in
vaccine efficacy is the availability of high versus low avidity T cell
repertoires for tumor clearance.
We previously generated high and low avidity RNEU420–429-
specificCD8
+TcellclonesderivedfromvaccinatedFVB/Nandneu-
N mice, respectively [11]. While these clones are of value in studying
antigen recognition, they are not ideal for studying mechanisms of
tolerance because they have already been through the tolerance
process.HerewereportthegenerationofRNEU420–429-specifichigh
and low avidity [12,13] TCR transgenic mice that derive from
these T cell clones. We show for the first time that tumor trafficking
and function of the high avidity RNEU420–429-specific T cells
when adoptively transferred into neu-N mice are suppressed by a
CD25
low Treg effector/memory subpopulation residing at the
tumor site. In addition, this suppression is reversed by depletion of
Tregs with Cy. In contrast, low avidity T cells specific for the
same antigenic epitope are not suppressed by this Treg sub-
population and do not become activated following depletion of these
Tregs. Thus, these findings elucidate one mechanism by which high
avidity tumor antigen-specific T cells are selectively suppressed.
These findings also provide a strong rationale for inhibiting specific
subsets of Tregs as a component of cancer-targeting vaccine
approaches.
Results
High avidity RNEU420–429-specific T cells mediate tumor
regression only following Treg depletion in tolerant
neu-N mice
We previously reported that Cy given one day prior to a neu-
targeted vaccine resulted in the partial depletion of Tregs,
activation of endogenous high avidity RNEU420–429–specific
CD8
+ T cells, and tumor clearance in 20–30% of neu-N mice
[11]. However, it is unclear whether the failure to cure the
majority of tumor bearing mice was due to the inefficient depletion
of Tregs, lack of induction of sufficient numbers of high avidity T
cells, or additional mechanisms of T cell regulation. RNEU420–429-
specific high and low avidity CD8
+ TCR transgenic mice were
therefore created to evaluate the fate of naı ¨ve antigen-targeted T
cells under conditions of T cell tolerance [11]. These mice were
confirmed to express high and low avidity T cell receptors specific
for the RNEU420–429 epitope (as previously reported for the T cell
clones from which they derived) using dilutional tetramer staining
of naı ¨ve TCR transgenic T cells isolated directly from the TCR
transgenic mice (Figure S1), and using ELISpot as a functional
analysis of avidity. Specifically, comparison of high versus low
avidity T cell populations isolated from vaccinated TCR
transgenic mice and assessed either directly or following a one
week stimulation with the RNEU420–429 peptide, demonstrated
that the high avidity T cell populations were better cytokine
producers when tested against NT2.5 tumors as targets (Data not
shown). To assess the in vivo function of each T cell population,
isolated naı ¨ve high and low avidity T cells were adoptively
transferred into tumor-bearing FVB/N and tolerant neu-N mice,
treated with combinations of either the specific 3T3neuGM
vaccine or the negative control 3T3GM mock vaccine, with or
without low dose Cy. 3T3GM mock vaccine was used as the
negative control in all studies in order to control for the non-
specific physiological effects of GM-CSF. Hence any differences
between groups are from the specific presence of neu in the
vaccine. FVB/N mice were used as positive control mice to assess
optimal T cell function in non-tolerant mice. FVB/N mice
receiving high avidity T cells and the 3T3neuGM vaccine with or
without Cy cleared tumor faster than mice receiving low avidity T
cells (Figure 1a, b) indicating that the high avidity T cells are
naturally more potent than the low avidity T cells even in mice
without tolerizing mechanisms. In addition, treatment with the
high avidity T cells and only the control 3T3GM mock vaccine
still controlled tumors in the FVB/N mice more effectively than
treatment with low avidity T cells and the 3T3GM mock vaccine
(Figure 1a, b) indicating that high avidity T cells can be activated
in non-tolerant mice bearing antigen expressing tumors even
without receiving an antigen containing vaccine.
The majority of neu-N mice (.75%) receiving Cy plus high
avidity T cells also cleared tumor rapidly, within one week of
adoptive transfer. After 30 days, tumors in these mice were
significantly smaller in size than tumors in mice treated with Cy
plus vaccine, without high avidity T cells (Figure 2a,p ,0.001
using both ANOVA and t test). In contrast, tumors in neu-N mice
receiving low avidity T cells all progressed, regardless of the
treatment they received (Figure 2b). In addition, the rate of
tumor growth in mice receiving Cy, 3T3neuGM vaccine, and low
avidity T cells, was similar to mice receiving Cy and vaccine alone.
These data indicate that Cy is required for the sustained in vivo
function of high avidity but not low avidity T cells in tolerant mice.
However, these studies failed to show a difference in tumor
clearance between mice receiving the 3T3neuGM vaccine versus
the 3T3GM mock vaccine when given with both Cy and high
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investigate whether a neu-targeted vaccine is needed for optimal
high avidity T cell function when Tregs are depleted, we
compared the mock versus the neu-targeted vaccine for the ability
to facilitate clearance of a larger tumor burden. When mice were
challenged with twice the number of tumor cells, a significantly
greater percentage of mice receiving the neu-targeted vaccine had
long-term tumor control (p,0.05, Figure 2c). Similar results
were seen if T cell transfer was delayed until 10 days post tumor
challenge allowing the tumors to develop longer (Data not shown).
Using titration experiments, we found that minimal number of
adoptively transferred T cells to eliminate large tumor burdens
was 4610
6 T cells. (Data not shown) Thus, both Treg depletion
and an antigen-specific vaccine are required for inducing the most
effective high avidity T cell response against larger tumor burdens
in these tolerant mice.
Figure 1. Adoptively transferred RNEU420–429-specific high
avidity T cells enhance tumor clearance in FVB/N mice. The
minimal tumorigenic dose was given to FVB/N mice on day 0; Cy was
given on day 2; vaccine or mock vaccine was injected on day 3; high
avidity or low avidity T cells were adoptively transferred on day 4.
Treatment groups are indicated in the figures. (A) Tumor growth after
high avidity T cell adoptive transfer into FVB/N mice. (B) Tumor growth
after low avidity T cell adoptive transfer into FVB/N mice. Data was
graphed as the tumor area vs. days (figures 1 A–B) after adoptive
transfer. *=p,0.05; **=p,0.001. Experiments were repeated three
times (n=10 mice per group).
doi:10.1371/journal.pone.0031962.g001
Figure 2. RNEU420–429-specific high avidity T cells enhance
tumor clearance in neu-N mice given Cy and vaccine. Neu-N mice
were treated as in Figure 1 and the Methods. (A) Tumor growth after
high avidity T cell adoptive transfer into neu-N mice. (B) Tumor growth
after low avidity T cell adoptive transfer into neu-N mice. (C) Twice the
minimum tumor dose was given to neu-N mice (1610
5 cells/mouse) on
day 0. Data was graphed as the tumor free probability vs. weeks
(Figure 2C) or tumor size (mm
2) vs. days (figures 2A–B) after adoptive
transfer. *=p,0.05; **=p,0.001. Experiments were repeated three
times (n=10 mice per group).
doi:10.1371/journal.pone.0031962.g002
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higher levels of cytokines when compared with low
avidity T cells in FVB/N and neu-N mice
Initial adoptive transfer studies demonstrated that high avidity T
cells are more capable of killing neu-expressing tumor cells than low
avidity T cells. To assess whether this difference correlated with
increased high avidity T cell persistence, we evaluated the percentage
of high avidity and low avidity T cells (TCR transgenic T cells are
Thy1.2
+ and neu-N and FVB/N mice are Thy1.1
+) recovered from
FVB/N and neu-N mice at 1, 3, and 5 weeks after adoptive transfer.
While high avidity T cells persisted for at least 5 weeks following
transfer into tumor-bearing FVB/N mice treated with the
3T3neuGM vaccine plus Cy (Figure S2a,p ,0.001), less than 2%
of both high avidity and low avidity T cells persisted .3w e e k si nneu-
N mice even following treatment with 3T3neuGM vaccine plus Cy
(Figure S2b). We previously reported that maximal Treg depletion
occurs2 days after Cy treatment in neu-N mice and returns to baseline
about one week later [11]. Therefore, the effects of Treg depletion on
T cell persistence would be expected to occur during T cell priming in
the first week after vaccine plus Cy treatment. We therefore
calculated the absolute numbers of T cells remaining in the tumor-
draining lymph nodes (TDN) and vaccine-draining lymph nodes
(VDN) of neu-N mice on days 3, 5, and 8 after adoptive transfer. Both
high avidity and low avidity T cells were found to migrate into the
VDN and TDN, regardless of the treatment (Figure 3a, b). In
addition, the highest numbers of T cells were detected in VDN and
TDN on day 3 after adoptive transfer, a finding consistent with
previous studies suggesting that the peak of endogenous T cell
priming occurs in the lymph nodes 3–4 days following treatment with
the 3T3neuGM vaccine plus Cy [14]. Thus, although there were a
higher number of high versus low avidity T cells detected in TDN
and VDN, differences in T cell persistence do not fully explain why
high butnotlowavidityT cellsdevelop tumorlyticfunctionfollowing
Treg depletion.
We therefore evaluated the activation status of the high avidity
and low avidity T cells in Cy plus 3T3neuGM-treated neu-N mice
on days 3 and 5 after adoptive transfer. Specifically, the absolute
number of IFNc-, TNFa-, and IL-2-secreting Thy1.2
+ cells in the
VDN, TDN, and non-draining lymph nodes (NDN, control lymph
nodes) were determined. Despite the persistence of similar
numbers of total high and low avidity adoptively transferred T
cells, there were significantly greater numbers of high avidity T
cells secreting activation-associated cytokines when compared to
low avidity T cells (Figure 4). IFNc is the main cytokine produced
by these activated high avidity T cells in tolerant neu-N mice, while
multiple cytokines (IFNc, TNFa, and IL-2) are produced following
adoptive transfer of high avidity T cells into non-tolerant mice
(Figure S3). Taken together, these findings suggest that the
tolerant environment in neu-N mice hinders the development of
the most potent polycytokine producing T cells, even when Tregs
are transiently suppressed during T cell priming. However, high
but not low avidity T cells transferred into tolerant mice are able
to reach a level of activation required to produce IFNc and
mediate tumor lysis.
Adoptively transferred high avidity but not low avidity T
cells upregulate integrin and CXCR3 expression in TDNs
in vaccinated and Cy treated neu-N mice
So far the data demonstrate that adoptively transferred high
avidity T cells can be activated to secrete cytokines to a greater
extent than low avidity T cells in 3T3neuGM plus Cy-treated neu-
N mice. However, activated T cells must also migrate from the
lymph nodes to the tumor microenvironment to effect tumor
clearance. It is still unclear whether there are also differences in
tumor migration efficiency between high and low avidity T cells in
neu-N mice. T cell expression of integrins and chemokines are
known requirements for T cell migration from the priming site to
the site of effector function [15,16]. Specifically, the VLA family of
Figure 3. High avidity T cells expand preferentially after adoptive transfer into Cy and vaccine-treated neu-N mice. Mice were injected
with 1610
6 tumor cells/mouse one week prior to Cy and vaccine treatment. High avidity or low avidity T cells were adoptively transferred one day
after vaccination. (A) The absolute # of Thy1.2 T cells were calculated in the tumor draining lymph nodes (TDNs) of neu-N mice on day 3 (White bars),
5 (Gray bars), and 8 (Black bars) after adoptive transfer (n=9 mice per group). (B) The absolute # of Thy1.2 T cells were calculated in the vaccine
draining lymph nodes (VDNs) on day 3 (White bars), 5 (Gray bars), and 8 (Black bars) after adoptive transfer (n=9 mice per group). Treatment groups
are as indicated. High/low=High or low avidity T cells, respectively. Cy=Cytoxan treated. Vaccine=3T3neuGM vaccine, Mock=3T3GM control
vaccine. Each experiment was repeated three times with similar results.
doi:10.1371/journal.pone.0031962.g003
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in models of tumor and inflammation [17,18,19,20,21]. We
therefore compared high and low avidity T cells for surface
expression of the VLA integrins b1 (CD29), a4 (CD49d), and a6
(CD49f), in spleens and TDNs, on days 3 and 5 after adoptive
transfer into tumor-bearing neu-N mice. High avidity T cells in
TDNs had significantly higher b1 integrin expression when
compared with low avidity T cells isolated from 3T3neuGM plus
Cy-treated (p,0.001) and 3T3neuGM only treated mice
(p,0.001 for both ANOVA and t test) (Figure 5a). High avidity
T cells from 3T3neuGM plus Cy-treated mice also expressed
significantly higher a4( p ,0.001 for both ANOVA and t test) and
a6( p ,0.001 for ANOVA analysis and p,0.05 for t test) integrins
than all other mouse groups (Figure 5b, c). Similar results were
observed for T cells isolated from spleen (data not shown). Thus,
Cy treatment leads to upregulation of T cell trafficking integrins
on high avidity but not low avidity T cells.
Chemokine receptor CXCR3 expression has also been reported
to be critical for T cell migration to target tissues expressing the
CXCR3 ligands CXCL9 and CXCL10. CXCL9 is produced in
the tumor-microenvironment in response to IFNc production, and
can attract CXCR3
+ T cells into the tumor [22,23]. To further
evaluate differences between high and low avidity T cell function
in tolerized mice, we analyzed CXCR3 expression on both high
avidity and low avidity T cells on days 3 and 5 after adoptive
transfer into tumor-bearing neu-N mice. High avidity T cells
isolated from the TDNs upregulated surface expression of CXCR3
to a greater extent than low avidity T cells from 3T3neuGM plus
Cy-treated mice at day 5 (p,0.05, Figure 5d). In contrast, high
avidity T cells from 3T3neuGM only treated mice had lower levels
of CXCR3 expression (p,0.001). In addition, we analyzed
CXCR3 and CXCL9 expression in neu-expressing tumors on
days 3 and 5 after adoptive transfer into tumor-bearing neu-N
mice. Interestingly, while tumors isolated from all mouse groups
produced low levels of CXCL9, neu-expressing tumors isolated
from mice receiving the 3T3neuGM vaccine, Cy, and high avidity
T cells, produced the highest levels of CXCL9 on days 3 and 5
after adoptive transfer (Figure S4). These data suggest that
CXCR3 expression is upregulated on high avidity T cells following
Cy treatment, allowing them to migrate to the CXCL9-producing
tumor. These data provide an additional mechanism by which
Tregs may preferentially regulate high avidity but not low avidity
T cells in tolerant mice.
Cy-mediated Treg depletion facilitates high avidity T cell
infiltration into neu-N mouse tumors
The adoptive transfer studies presented thus far demonstrate
that Cy given in sequence with an antigen-targeted vaccine to
deplete Tregs selectively increases high but not low avidity T cell
persistence, activation, and integrin expression in VDNs and
TDNs. To further evaluate Cy-mediated high avidity T cell
function, we investigated the numbers and quality of high avidity
T cells migrating into the tumor after various treatments. High
avidity and low avidity T cells were adoptively transferred into
tumor-bearing FVB/N and neu-N mice receiving either the
3T3neuGM or control 3T3GM mock vaccines. Significantly
greater numbers of high avidity T cells were isolated from the
tumors on day 5 after adoptive transfer following vaccine plus Cy
Figure 4. Enhanced cytokine secretion in high avidity T cells post-transfer into Cy and vaccine-treated neu-N mice. On day 3 and day 5
after adoptive transfer, lymphocytes isolated from the non-draining lymph nodes (NDNs, White bars), VDNs (Black bars), and TDNs (Gray bars) were
analyzed for the ability to secrete IFNc, TNFa, and IL-2 secretion by ICS, and the absolute # of activated Thy1.2 cells was calculated (n=3 mice per
group). Treatment groups are as indicated. High/low=High or low avidity T cells, respectively. Cy=Cytoxan treated. Vaccine=3T3neuGM vaccine,
Mock=3T3GM control vaccine. Each experiment was repeated three times with similar results.
doi:10.1371/journal.pone.0031962.g004
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(p,0.05 using ANOVA and t test, Figure 6a) and few low
avidity T cells infiltrated tumors regardless of the treatment
(Figure 6b). Interestingly, the peak of high avidity T cell
infiltration into tumors occurs about 2 days after the peak of high
avidity T cell IFNc secretion and integrin upregulation in TDNs.
As expected, both low avidity and high avidity T cells infiltrated
the tumors of vaccinated FVB/N mice, even without Treg
depletion (data not shown). Thus Cy-mediated Treg depletion is
required for high avidity but not low avidity T cell activation and
tumor migration in tolerized mice. Low avidity T cell migration
likely requires additional activation signals that are not available in
non-tolerant hosts.
While CD8
+ T cell trafficking into the tumor is an important
predictor of tumor clearance, the ratio of effector T cells to
Tregs (Teff/Treg) and the activation status of effector T cells in
the tumor microenvironment are also important tumor
clearance factors [24,25,26,27,28]. We therefore compared
the number of tumor infiltrating high avidity T cells to the
number of CD4
+Foxp3
+ Tregs in the tumor of vaccinated mice
with and without Cy treatment (Figure 6c). Cy treatment
groups did indeed have a higher Teff/Treg ratio in the tumor
when compared to non-Cy treated groups (p,0.05 using
ANOVA and t test). To confirm that these high avidity T cells
in TIL are capable of effector function, ICS studies were
performed and demonstrated that up to 30% of the high avidity
TIL produce IFNc (Figure 6d). These data confirm through
ex-vivo analysis, that high avidity T cells trafficking into the
tumors are present in high effector:Treg ratios, and are capable
of producing IFNc.
Next, we used biodistribution and imaging studies to verify the
selective trafficking of high avidity versus low avidity T cells into
the tumors of tolerant neu-N mice. Tumor-bearing neu-N mice
received the 3T3neuGM or 3T3GM mock vaccines with and
without Cy, and high or low avidity T cells, followed by injection
with indium-111-labeled Thy1.2 mAb on day 4 after T cell
transfer. Twenty-four hours following Thy1.2 monoclonal anti-
body injection, tumors were excised and measured for indium-111
content. The mean tumor radioactivity concentration was 2-fold
higher in mice receiving 3T3neuGM vaccine plus Cy with high
avidity T cells than in the non-Cy groups (p,0.05 using ANOVA
and t test) (Figure 7a). These findings were further confirmed
using SPECT/CT imaging, in vivo (Figure 7b). Finally, we
performed in situ immunofluorescence staining of resected tumors
for Thy1.2 expression (Figure 7c). From these studies it is clear
that only Thy1.2
+ high avidity T cells infiltrate tumors
predominantly following Cy treatment. These results confirm that
high avidity T cells have the capacity to infiltrate tumors of
tolerant mice if the mice are given immune-modulating doses of
Cy in combination with vaccine.
Figure 5. Cy plus vaccine enhances VLA-4, VLA-6, and CXCR3 expression on high avidity T cells. On day 3, TDN lymphocytes from neu-N
mice were stained for (A) b1 integrin expression, (B) a4 integrin, or (C) a6 integrin, and the Mean Fluorescent Intensities (MFI) calculated. (n=3mice/
group). Isotype control MFIs were b1 integrin ,20, a4 integrin ,50–100, a6 integrin ,30. (D) TDN lymphocytes from neu-N mice on day 5 were
stained for CXCR3 and the %CXCR3
+ of Thy1.2 cells was calculated (n=5 mice/group). MFI isotype for CXCR3 is ,10. *=p,0.05, **=p,0.001. High/
low=High or low avidity T cell transfer, respectively. Cy=Cyclophosphamide treatment. Vaccine=3T3neuGM vaccine, Mock=3T3GM control vaccine.
Each experiment was repeated three times with similar results.
doi:10.1371/journal.pone.0031962.g005
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low Tregs migrate into tumors and mediate high
avidity T cell suppression
While Cy allows for enhanced high avidity T cell trafficking into
tumors, it does not deplete the systemic Treg population as
extensively as other Treg-depleting agents. One explanation for
this difference is that each Treg inhibiting agent affects different
Treg subsets. Recent studies have characterized distinct Treg
subpopulations that express different activation molecules, migra-
tion integrins, and levels of the IL-2 receptor, CD25. Initial flow
cytometry experiments characterizing the CD4
+Foxp3
+ T cells
that infiltrate neu-expressing tumors showed that Cy depletes a
population of CD4
+Foxp3
+ T cells that express an activated/
migratory phenotype (ICOS
+, b-integrin
high, CD44
+/high,
CD62L
low) (Data not shown), Subsequently this subset of Tregs
was further analyzed for CD25 expression following treatment of
neu-N mice with 3T3neuGM vaccine alone or 3T3neuGM plus Cy
and high avidity T cells. Cy given with the 3T3neuGM vaccine
reduced both the percent and absolute number of CD25
low Tregs
in the spleen compared to vaccine alone (28% versus 52% of the
CD4
+Foxp3
+ cells were CD25
low, respectively) (Figure 8a, b).
The reduction in absolute numbers of CD25
low Tregs with Cy
treatment in spleen reached significance (p,0.05 and p,0.001,
respectively using both ANOVA and t test, Figure 8b, c). Trends
were similar but not statistically significant in TDNs (Data not
shown). These data provide additional support that Cy preferen-
tially targets a CD25
low Treg population.
CD25
low Tregs have been described as an inflammation-
seeking, migratory effector/memory population responsible for
suppression in the periphery, while CD25
high Tregs have been
described as a lymph-node resident population [7,8]. To further
assess the migration potential and activation status of these two
Treg subsets, Tregs from neu-N mice treated with vaccine and high
avidity T cells were isolated and analyzed based on CD25
expression. Analysis of each population revealed that the
Figure 6. Cy-mediated Treg depletion increases high avidity T cell tumor trafficking in neu-N mice. Neu-N mice were treated as in
Figure 3.( A and B) On day 3 (White bars) and day 5 (Gray bars) after adoptive transfer, the absolute number of Thy1.2
+ cells/mg of tumor was
calculated for each treatment group (n=3 mice/group). (C) On day 5 after adoptive transfer the ratio of Thy1.2
+ cells/CD4
+Foxp3
+ cells was calculated
(n=3 mice/group). (D) Lymphocytes from tumors on day 5 after adoptive transfer were stimulated as described in the methods and the %Thy1.2
+
cells producing IFNc after RNEU420–429 stimulation was calculated after NP stimulation was subtracted (n=5mice/group). *=p,0.05. High/low=High
or low avidity T cell transfer, respectively. Cy=Cyclophosphamide treatment. Vaccine=3T3neuGM vaccine, Mock=3T3GM control vaccine. Each
experiment was repeated three times with similar results.
doi:10.1371/journal.pone.0031962.g006
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+Foxp3
+CD25
low Tregs expressed higher levels of the
activation markers ICOS, CD44, CTLA-4, and GITR, and the
migration markers b1 integrin, LFA1, and CXCR3 and lower
levels of the lymph node homing marker CD62L when compared
with the CD4
+Foxp3
+CD25
high Tregs (Figure 9a, b). Thus,
CD25
low Tregs express an activated phenotype [7,8] that appears
to be responsible for suppressing high avidity T cells infiltrating
tumors.
Next, we assessed whether CD4
+Foxp3
+CD25
low Tregs can
suppress antigen-specific high avidity T cells using an in vitro
suppression assay. Naı ¨ve CFSE-labeled high avidity T cells were
incubated with CD11c
+ DCs from 3T3neu GM vaccine-treated
FVB/N mice for 3 and 5 days to stimulate their proliferation.
These vaccine primed DCs from non-tolerized mice would be
expected to provide optimal high avidity T cell activation. Flow
cytometry sorted CD4
+Foxp3
+CD25
high or CD4
+Foxp3
+CD25
low
Tregs isolated from Foxp3
GFP neu-N mice that were vaccinated with
3T3neuGM one week earlier were then added to the high avidity
T cell cultures. Treatment of neu-N mice with vaccine alone would
be expected to induce optimal numbers of Tregs. High avidity T
cells were analyzed for CFSE dilution after 3 and 5 days of culture.
Positive controls included high avidity T cells with DCs alone, and
high avidity T cells with DCs plus control naı ¨ve CD4
+ T cells
isolated from FVB/N GFP mice. As expected, the addition of
FVB/N CD4
+ T cells increased the proliferation of high avidity T
cells above that seen with DCs and high avidity T cells alone.
However, high avidity T cell proliferation was suppressed at 3 and
5 days in the groups that received either CD25
high or CD25
low
Tregs, indicating that CD25
low Tregs are indeed capable of
suppressing tumor-specific high avidity T cell proliferation
(Figure 10a). In support of these findings, both Treg subsets
were confirmed to express TGFb and IL-10 by qRT-PCR (data
not shown). Similarly, these same CD4
+Foxp3
+CD25
low Tregs
derived from vaccinated Foxp3
GFP neu-N mice suppressed high
avidity T cell IFNc secretion in vivo after they were transferred into
tumor bearing FVB/N mice treated with the 3T3neuGM vaccine
and high avidity T cells (Figure 10b). To further establish that the
CD25
low Tregs are the predominant Tregs that traffic into tumors,
we evaluated the percent of Tregs found in tumors after each Treg
subpopulation was adoptively transferred into tumor bearing mice.
Neu-N mice were given 3T3neuGM vaccine plus Cy, and
adoptively transferred high avidity T cells. CD25
low CD4
+Foxp3
+
or CD25
high CD4
+Foxp3
+ Tregs (5610
5 per mouse) from
vaccinated Foxp3
GFP neu-N mice were also adoptively transferred
on the same day as the high avidity T cells. Five days later, the
percentage of transferred GFP
+ Treg subsets within the total
CD4
+Foxp3
+ population was evaluated in the spleens, VDNs,
TDNs, and tumors. Although both Treg subsets traffic into the
lymph nodes and spleen, the CD25
low Tregs traffic to a
Figure 7. Confirmation of increased high avidity T cell tumor
trafficking by in vivo imaging. (A) Neu-N mice were tumor
challenged and treated as in the Methods. One day after T cell
adoptive transfer mice were treated with In-111 labeled anti-Thy1.2, the
tumors isolated and the radiation content analyzed as described in
Methods. Isotype=Isotype control treatment group. Tumor radioactiv-
ity concentration was reported as the average % injection dose/g of
tumor (n=3mice/group). (B) neu-N mice treated as in 7A,a n d
underwent SPECT/CT imaging. Coronal (left panel) and transverse (right
panel) cross-sections through the tumor are shown for each treatment.
(C) Tumors were collected on day 5 after adoptive transfer and
immunofluorescence stained for Thy 1.2. *=p,0.05. High/low=High or
low avidity T cell transfer, respectively. Cy=Cyclophosphamide
treatment. Vaccine=3T3neuGM vaccine. Mock=3T3GM Control Vac-
cine. These experiments were repeated 2–3 times with similar results.
doi:10.1371/journal.pone.0031962.g007
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high
Tregs (p,0.05 using both ANOVA and t test) (Figure 10c).
These data provide additional support that the CD25
low Treg
population is primarily responsible for high avidity T cell
suppression in the tumor microenvironment.
Discussion
We previously reported that high avidity CD8
+ T cell
populations specific for the immunodominant neu-derived epi-
tope, RNEU420–429, are recruited to kill neu-expressing tumors
following treatment with a neu-expressing vaccine and low dose
Cy as a method to deplete Tregs. Here we report three new
findings that for the first time elucidate the mechanism by which
Tregs suppress high avidity T cell activation and migration in the
immune tolerant environment of neu-N mice. First, high avidity
cancer antigen-targeted T cells can effectively eradicate develop-
ing tumors in tolerant hosts when efficient numbers of activated T
cells are available. However, activation and persistence of efficient
numbers of high avidity T cells is only possible following reduction
of Treg numbers. Importantly, we show for the first time that
Tregs appear to be the major regulator of these high avidity
effector T cells. Second, we also show for the first time that
antigen-targeted low avidity T cells are unable to persist long-term
and reach a necessary threshold of activation in tolerant hosts,
even with Treg reduction. Third, a Cy-sensitive Foxp3
+CD25
low
effector/memory Treg sub-population present in tolerant mice is
the primary mediator of antigen-targeted high avidity T cell
suppression within the tumor microenvironment.
Ideal vaccines should induce antigen-specific high avidity T cells
that can migrate to sites of inflammation and express multiple
effector cytokines [4,29,30,31]. In practice, vaccines do induce
high avidity T cells specific for infectious and cancer-associated
antigens when administered prior to antigen exposure. However,
there is an ongoing debate in the literature as to whether cancer
antigen-specific high avidity T cells exist in the periphery of
cancer-bearing hosts because many of these antigens are altered
self proteins. Some studies have suggested that high avidity T cells
are deleted, leaving only low avidity T cells for vaccine activation
[32]. Other studies have shown that high avidity antigen-targeted
T cells exist, but are tolerized and unable to mediate tumor
clearance [6,33,34]. We previously reported that Cy mediated
Treg depletion given in sequence with a neu-targeted vaccine
induces endogenous high avidity T cells that mediate tumor
clearance in 20–30% of mice [11]. These prior studies could not
address whether the low number of treatment successes was due to
the existence of yet undefined tolerance mechanisms or the
inability to induce large enough numbers of antigen-specific high
avidity T cells. Using the transgenic T cells described here to
model endogenous T cells, we demonstrate that larger numbers of
vaccine-activated high avidity T cells are necessary to treat
developing tumors in tolerized mice. Furthermore, these data
suggest that vaccination alone is not enough to activate the
number of endogenous T cells required for tumor clearance, and
that a significant reduction in the numbers of a specific subset of
Tregs is required to allow efficient vaccine activation of high
avidity T cells. Thus, these data show that Tregs are indeed a main
mechanism by which high avidity tumor antigen-specific T cell
function is suppressed.
In addition to inducing high avidity T cells, an ideal vaccine
should also induce a sufficient memory response to fight off future
antigenic challenges [35,36]. Our studies also show that
approximately 60% of mice given Cy, vaccine, and adoptive
transfer of high avidity T cells can resist a second tumor challenge
Figure 8. Cy preferentially depletes CD25
lowFoxp3
+ Tregs. Neu-N mice were treated as in Figure 3 and the Methods. Lymphocytes from
spleens were collected on day 3. (A) CD4
+Foxp3
+ Tregs were analyzed for CD25 expression. Definition of CD25
high vs. CD25
low is based on isotype
control. CD25
low cells=gray fill under the histogram. (B) Absolute # CD25
lowCD4
+Foxp3
+ Tregs calculated in spleens. (C) Absolute number of
CD25
highCD4
+Foxp3
+ Tregs calculated in spleens. High=high avidity T cell transfer, Cy=Cyclophosphamide treatment, Vaccine=3T3neuGM vaccine
treatment. *=p,0.05. These studies were repeated three times with similar results (n=3 mice/group).
doi:10.1371/journal.pone.0031962.g008
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regimen can induce a partial memory type response. At this time
point, Thy1.2
+ high avidity T cells comprise a detectable
population of the CD8
+ T cells with effector and central memory
phenotypes in neu-N mice that wanes at 5 weeks (Figure S2, and
Data not shown). The partial response may be due to the re-
establishment of tolerance in this system either by the re-
establishment of Treg numbers, as we have shown, or by an as
yet undetermined mechanism [11]. Future experiments will
address the longevity of the high avidity response in this system.
However, we hesitate to make definitive conclusions regarding the
memory phenotype of our adoptively transferred T cells, as others
have clearly demonstrated that adoptively transferring high
numbers of T cells alters the effector memory/central memory
development ratio away from the endogenous situation [37,38,39].
Partial Treg depletion using low dose Cy plus a neu-targeted
vaccine allowed for enhanced persistence, activation, and tumor-
trafficking of adoptively transferred high avidity T cells, leading to
tumor clearance in tolerant neu-N mice. Thus, the availability of
sufficient high avidity T cells alone is likely not enough to treat
tumors in tolerant hosts. Instead, Cy treatment, either through
Treg reduction or another mechanism, facilitates efficient high
avidity T cell activation, persistence, and tumor trafficking. Studies
have shown that lymph node residing T cells upregulate VLA-4,
VLA-6, and CXCR3 in order to migrate to CXCL9 producing
tumors [15,18,20]. In our model, high avidity T cells transferred
into Cy-treated neu-N mice upregulated these trafficking receptors
after adoptive transfer, allowing for tumor-infiltration, and tumor
clearance by one week after Cy administration, which is the same
time-point when depleted Treg populations begin to repopulate
the tolerant host [11], and the transferred high avidity T cells lose
IFNc production. Thus, Cy-mediated Treg depletion allows high
avidity T cells to upregulate the migration and activation signals
necessary for tumor trafficking and anti-tumor activity. Until
methods are available to deplete Tregs for longer than 1–2 weeks,
it is not possible to determine whether vaccine induced
endogenous T cells are capable of reaching the numbers achieved
with adoptively transferred high avidity T cells that are required
for tumor control in the majority of mice.
Although adoptively transferred high avidity T cells areefficiently
activated to clear tumor in tolerant mice, their cytokine secretion
capacity appears limited to IFNc secretion. In contrast, these same
high avidity T cells produce multiple cytokines (IFNc, IL-2, and
TNFa) when transferred into tumor-bearing non-tolerant FVB/N
mice. Other groups have suggested that TNFa expression correlates
with better effector function, cell persistence [40], and clinical
outcomes [41]. Thus, these data imply that a reduction in Treg
numbers alone is not sufficient to optimally activate high avidity T
cells. It is likely that fewer numbers of activated high avidity T cells
would be required to clear the same tumor burden in tolerant neu-N
mice if these T cells were optimally activated. In support of this
concept, the activation state of the high avidity T cells has recently
been implicated in their ability to promote tumor clearance.
Specifically, central memory T cells have been described as more
‘‘fit’’ to mediatetumor clearance dueto their less-differentiated state
and higher proliferative capacity [42,43,44]. Activation of termi-
nally-differentiated high avidity T cells is thought to lead to weaker
responsesdueto theirlimitedproliferation.However, high avidity T
cells, including central memory cells, are often exhausted due to
chronic tumor antigen stimulation and may exist in a ‘‘corrupted’’
or tolerant state [44]. Thus, additional studies are needed to further
clarify the role that the T cell activation state plays in tumor
clearance in tolerant hosts.
Many studies have also focused on antigen-targeted low avidity
T cell activation and function due to the predominance of low
avidity T cells in cancer-bearing hosts. Previous studies suggested
that low avidity T cells remain ignorant of antigen expression and
therefore do not mount a successful tumor-specific response
[32,45,46], while others suggest that CD4
+ T cell help enhances
low avidity T cell function allowing for some degree of tumor
destruction [26,46]. While those studies attempted to address the
role of low avidity T cells in tumor-bearing mice, none had
available a source of naı ¨ve low avidity CD8
+ TCR transgenic T
cells specific for a natural tumor antigen. Here, we show that neu-
specific low avidity T cells are capable of activation when
adoptively transferred into a non-tolerant environment. In neu-N
mice, however, low avidity T cells were unable to reach a level of
activation necessary for adequate IFNc secretion, integrin
upregulation, or tumor infiltration. As a result, these low avidity
cells did not affect tumor clearance, and their activation and
migration status was not altered by Treg reduction. The difference
in low avidity T cell function in the non-tolerant versus tolerant
environment is likely due in part to the presence of effective CD4
+
T cell help in non-tolerant mice. Our finding agrees with other
Figure 9. CD25
lowFoxp3
+ Tregs demonstrate an effector
phenotype. (A) CD4
+Foxp3
+CD25
high and CD4
+Foxp3
+CD25
low Tregs
from high avidity T cell and vaccine treated mice analyzed for
expression of ICOS, CTLA-4, GITR, and CD44. (B) CD25
high and
low Tregs
were analyzed for b1 integrin, LFA-1, CD62L, and CXCR3. CD25
high
histograms=Black line. CD25
low histograms=Dotted line. These studies
were repeated three times with similar results (n=3 mice/group).
doi:10.1371/journal.pone.0031962.g009
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+ T cell help, low avidity
CD8
+ T cells can become active and infiltrate the tumor
microenvironment [47,48]. Since low avidity T cells were able
to migrate into the tumor, but still were not as potent as the high
avidity T cells in rejecting tumor in non-tolerant FVB/N mice, it is
likely that alternative mechanisms are blocking optimal low avidity
T cell activation even in a more immune permissive setting.
Both CD25
high and
low Treg subsets effectively suppress high
avidity T cells in vitro, yet we only observed a trend in suppression
with an in vivo suppression assay. One possibility that explains why
the in vivo suppression assay results failed to reach significance is
the technical difficulty of isolating sufficient numbers of Tregs that
maintain stable function after adoptive transfer. It is also possible
that systemic evaluation of CD25
low Treg suppression of high
avidity T cells is not an optimal assay since CD25
low Tregs likely
function best within the tumor micro-environment, where they
preferentially migrate [49]. Some studies have shown that tumor-
specific T cells are tolerized at the tumor site. Although technically
difficult, future in vivo studies will attempt to address where
CD4
+Foxp3
+CD25
low Tregs affect tolerance.
Emerging data demonstrate that even among CD4
+FoxP3
+
Tregs, there are sub-populations with different functions and sites
Figure 10. CD25
lowFoxp3
+ Tregs suppress high avidity T cells and traffic preferentially to the tumor. (A) CD25
low and CD25
high CD4
+
Treg cells suppress high avidity T cell activation in vitro. CD25
low or CD25
high CD4
+ FoxP3
gfp+, DC, and CFSE-labeled high avidity Thy1.2
+ CD8
+ neu-
specific T cells were mixed as described in the Methods. CFSE dilution was measured on days 3 and 5. CD4
+ T cells from FVB/N mice were used as
controls. High+DCs=High avidity T cells+DCs. High+DCs+CD4s=High avidity T cells+DCs+FVB/N CD4
+ T cells, (B) CD25
lowCD4
+FoxP3
+ Tregs trend
toward suppression in vivo. neu-N/FoxP3
gfp mice were given tumor and vaccinated as in the Methods. CD4
+CD25
low Tregs were isolated 1 week later
and transferred to FVB/N-TgN(TIE2GFP)287Sato mice which were then vaccinated. CD8
+ T cells were isolated 2 weeks later and tested for the ability to
secrete IFNc in response to RNEU420–429. Data are presented as % RNEU420–429-specific, IFNc
+ of CD8
+ T cells. This experiment was done twice with
similar results. (C) CD25
low Tregs traffic preferentially to the tumor. neu-N mice received tumor and one week later received Cy, vaccine, 6610
6 high
avidity T cells, and 5610
5 CD25
low or CD25
high CD4
+GFP
+ Tregs. On day 5 CD25
low or CD25
high CD4
+GFP
+ Tregs recovered from tumors, spleens, TDNs,
and VDNs were enumerated as a fraction of the total # of FoxP3
+ T cells at each site (n=3mice/group). *=p,0.05. This experiment was repeated
three times with similar results.
doi:10.1371/journal.pone.0031962.g010
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attempted to characterize an inflammation-seeking and highly
suppressive CD25
low Treg effector/effector memory population
[7,8,50,51]. The surface markers expressed by these Tregs point
towards their critical suppressive role in tumor-bearing hosts. High
b1 integrin, LFA-1, and CXCR3 expression on CD25
low Tregs
allow for increased blood vessel extravasation and migration into
the tumor, while the low levels of CD62L indicate a migratory
phenotype. The importance of ICOS expression by Tregs has
been well documented and may be responsible for increased IL-10
production [52,53], while CD44, CTLA-4, and GITR are also
expressed highly on antigen experienced or activated Tregs [54].
Although a few studies have shown that this CD25
low suppressor T
cell population also express CD103 [7], we were unable to detect
any Treg CD103 expression on CD25
low Tregs in neu-N mice.
Other groups have describe Tbet expression by CD25
low Treg
cells [8]. The CD25
low Tregs in our model also express high levels
of CXCR3 and Tbet. (Data not shown) Taken together, these
findings suggest that the CD25
low Tregs identified in this study
likely represent an effector/memory Treg subpopulation similar to
that described by other groups.
Treg depletion is believed to be an important strategy in
enhancing cancer vaccine efficacy in tumor-bearing hosts. Many
pre-clinical and clinical studies have successfully used a variety of
Treg-depleting agents to reduce tolerance and activate CD8
+ T
cell populations in the setting of tumor development [55,56]. Treg
depletion strategies strive to deplete all Treg populations because
we do not understand which populations predominantly prevent T
cell activation in tumor-bearing hosts. Therefore, the study of Treg
subpopulations may allow the development of new Treg depleting
agents that remove the Tregs responsible for inhibiting cancer
antigen-targeted T cells and preserve Treg populations required
for inhibiting autoimmune disease. Thus, the surface activation
markers expressed on the subset of Tregs that migrate to the tumor
may be important targets for future Treg depletion strategies to
improve vaccine therapy. This study also verifies the importance of
this CD25
low Treg population in a clinically relevant model of
breast cancer.
In addition to its CD25
low Treg-depletion effects, Cy may also
have other beneficial effects in a tumor-bearing host. A few studies
have shown that in certain models, Cy increases type I IFN
production and activates DCs that increase effector cell popula-
tions [57,58]. These findings may explain the apparent longer-
term effects of Cy treatment on the persistence and activation of
adoptively transferred high avidity T cells into FVB/N mice when
compared with the short-term effects on the same T cells
adoptively transferred into neu-N mice. It is possible that Cy
depletes tolerogenic DCs or other antigen presenting cells
responsible for activating Tregs [57,59]. The resulting shift in
DC homeostasis would ultimately lead to increased activation of
tumor-specific CD8
+ T cells. This effect would likely be short-term
in neu-N mice due to the regeneration of such antigen presenting
cell populations, whereas the effect would be longer-term in non-
tolerant FVB/N mice. In addition, by increasing type I IFNs and
DC activation, Cy may increase T cell survival and memory
development [58,60]. Recently there has been a link postulated
between lymphopenia and autoimmune disease. Since Cy does
cause mild lymphopenia, in the neu-N system, a mild form of
autoimmunity may be induced leading to tumor destruction [61].
Finally, a recent study suggested that Cy may promote the
differentiation of non-Treg CD4
+ T cells into pro-inflammatory T
helper 17 cells that enhance anti-tumor immunity [62]. Therefore,
Cy may have multiple tolerance-reducing effects that lead to
enhanced anti-tumor activity.
In conclusion, these findings demonstrate for the first time that
high avidity antigen-targeted CD8
+ T cells are regulated
predominantly by Tregs in cancer bearing hosts. In addition, a
subset of effector/memory Tregs are largely responsible for
suppressing high avidity T cells in the tumor microenvironment.
Low avidity tumor-specific T cells can function in a non-tolerant
host following antigen-targeted vaccination but require as of yet
undefined activation signals to achieve adequate function in
tolerant hosts and optimal function in non-tolerant hosts. Thus,
through the use of high avidity and low avidity T cell populations
specific for the same antigen, the specific requirements for T cell
activation, trafficking, and function within the tumor micro-
environment can be delineated under different tumor-bearing
conditions. Ultimately, this information will lead to improved
combinatorial immune based approaches for cancer therapy.
Methods
Ethics Statement
All mice were treated according to AALAC approved protocols
and guidelines outlined by the Johns Hopkins School of Medicine’s
Animal Care and Use Committee, specifically approved under
protocol number MO10M262.
Mice
All mice used were females between 6–12 weeks of age. FVB/N
mice were obtained from Harlan Laboratories (Frederick, MD).
Neu-N mice were purchased from the Jackson Laboratory (Bar
Harbor, ME) and bred in the Johns Hopkins animal facility. FVB/
N Thy1.2
+ mice were generated by backcrossing the Thy1.2 gene
from BALB/c mice onto the FVB/N background for 10
generations.
TCR transgenic mice were created from high avidity and low
avidity RNEU420–429-specific T-cell clones, which were generated
from vaccinated FVB/N and neu-N mice, respectively [11]. The
high avidity clone expresses the TCR variable regions Vb4 and
Va1.1, while the low avidity clone expresses the TCR variable
regions Vb2 and Va5. cDNA was isolated from the clones using
the SMART-RACE kit (Clontech) and primers HT-27
(TCGGTGAACAGGCAGAGGGTG) and HT-2 8(CTTTT-
GATGGCTCAAACAAGGAGA), which are specific for the
alpha and beta constant regions of the TCR, respectively. Chains
were cloned into pCR2.1 using the TOPO-TA cloning kit
(Invitrogen). Artificial introns and restriction sites for cloning were
constructed for the alpha and beta chains. The constructs were
then cloned into cassette vectors as described by Kouskoff et al.
[63,64]. Low avidity a and b chains were PCR amplified from the
genomic sequence and cloned directly into the Kouskoff cassette
vectors [64].
Founder mice were selected following antibody staining for Vb4
(clone KT4) and Vb2 (clone B20.6) chains for the high avidity and
low avidity mice, respectively (Figure S1a–d). Since antibodies to
the Va1.1 and Va5 chains are not commercially available, the Va
chain usage was confirmed through evaluation of mRNA
expression levels (data not shown) [11]. CD8
+ T cells from each
mouse colony were confirmed to have equivalent levels of CD3,
CD8, or Vb expression (Figure S1e). The avidity of the TCR
transgenic T cells was assessed by flow cytometry using dilutional
tetramer staining as previously described [11], and confirmed to
be of similar avidity levels to the clones from which they derived
(Figure S1f). High avidity and low avidity mice were bred with
FVB/N Thy1.2
+ mice, and pups tested for Vb and Thy1.2
expression by antibody staining. Avidity status was confirmed by
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adoptively transferred TCR transgenic T cells in vivo.
FVB/N-TgN(TIE2GFP)287Sato mice were purchased from
Jackson Labs. Foxp3
gfp knock-in mice were provided by Alexander
Rudensky (University of Washington, Seattle, WA), and back-
crossed to the FVB/N background for 10 generations and then
crossed to the neu-N background to generate neu-NFoxp3
gfp mice
[65].
Cell lines and media
NT2.5, the neu-overexpressing mammary tumor cell line, was
generated from a spontaneously arising tumor in a neu-N mouse as
previously described [66,67]. NT2.5 was maintained in RPMI
with 20% FBS, 1.2% HEPES, 1% L-glutamine, 1% non-essential
amino acids, 1% sodium pyruvate, 0.5% penicillin-streptomycin,
0.2% insulin, and 0.02% gentamycin. The 3T3neuGM vaccine
cell line (3T3 cells genetically modified to express both neu and
GM-CSF (GM)), and the 3T3GM cell line (mock vaccine that does
not express neu) have been previously described [9]. Vaccine lines
were maintained in DMEM supplemented with 10% bovine calf
serum, 1% sodium pyruvate, and 0.5% penicillin-streptomycin,
with methotrexate selection added to the 3T3neuGM line. The
T2D
q cells [9] were and maintained as previously described in
RPMI supplemented with 10% FBS, 1% L-glutamine, 1% sodium
pyruvate, 1% non-essential amino acids, 0.5% penicillin-strepto-
mycin, and 0.68% hygromycin B.
Peptides and antibodies
The RNEU420–429 (PDSLRDLSVF) and the negative control
peptide LCMV NP118–126 (RPQASGVYM) [68] peptides were
produced in the Johns Hopkins Biosynthesis and Sequence Facility
at a purity .95%. Antibodies used for analysis were anti-Thy1.2-
PerCP (Biolegend), anti-TNFa-allophycocyanin (BD Pharmingen),
anti-IL-2-FITC (BD Pharmingen), anti-IFNc-PE (BD Pharmin-
gen), anti-CD4-FITC (BD Pharmingen), anti-CD25-PerCP (Bio-
legend), anti-CD62L-allophycocyanin (BD Pharmingen), anti-
ICOS-PE (anti-CD278, BD Pharmingen), anti-CD44- allophyco-
cyanin (BD Pharmingen), anti-GITR-allophycocyanin (eBios-
cience), anti-CTLA-4-PE (BD Pharmingen), anti-CD29-PE
(eBioscience), anti-LFA-1-PE (anti-CD11a, BD Pharmingen), and
anti-CXCR3-allophycocyanin (Biolegend).
Tumor, vaccine, chemotherapy, and antibody
administration procedures
For tumor-clearance studies, FVB/N and neu-N mice received
subcutaneous (s.c.) injections into the right upper mammary fat
pad of 2610
6 and 5610
4 NT2.5 cells [69,70] in 0.1 ml PBS,
respectively. For tumor infiltrating lymphocyte (TIL) and lymph
node analysis experiments, FVB/N and neu-N mice received
5610
6 and 1610
6 NT2.5 cells, respectively. Tumor cells were
injected 3 days prior to vaccination, except for TIL and lymph
node experiments, where tumor was given 8 days prior to
vaccination. Cyclophosphamide (Cy) was injected intraperitone-
ally (i.p.) at a dose of 100 mg/kg in 0.5 ml PBS. Cy was given
24 hrs prior to vaccine administration. The vaccine (3T3neuGM
cells) and mock vaccine (3T3GM cells) were administered s.c. at a
dose of 3610
6 cells per mouse, divided into three 0.1 ml injections
in PBS, and distributed equally among the left upper limb, and
right and left lower limb.
Adoptive transfer studies
Thy1.2
+ TCR transgenic high avidity and low avidity CD8
+ T
cells were isolated by CD8 negative selection using Dynal CD8
isolation kits (Invitrogen). After isolation, cells were adoptively
transferred at 6610
6 cells per mouse (unless otherwise stated) in
0.5 ml PBS via tail vein injection, one day after vaccine
administration. Four million high avidity T cells was determined
to be the minimal adoptive transfer dose necessary to achieve
.75% tumor clearance in Cy+ vaccine treated neu-N mice (data
not shown). A 6610
6 T cell dose was administered to maximize
cell recovery from various tissues for analysis during cytokine and
trafficking experiments after adoptive transfer. T cells were
isolated from spleens, lymph nodes, and tumors 3, 5, and 8 days,
and 3 and 5 weeks after adoptive transfer and analyzed by flow
cytometry as described below.
Flow cytometry, intracellular cytokine staining (ICS), and
tetramer analyses
At the time points described above, spleens and lymph nodes
were collected from adoptively transferred mice and mashed
through 40 mM nylon cell strainers. Tumors were mashed through
cell strainers, enzymatically digested using collagenase (1 mg/ml,
Gibco) and Hyluronidase (25 mg/ml, Sigma), and plated on flasks
to separate adherent tumor cells from lymphocytes in suspension.
Isolated lymphocytes were assessed for activation status by ICS for
cytokine expression (IFNc, IL-2, and TNFa) using a mouse ICS kit
(BD Biosciences). Lymphocytes were incubated at 37uC
with peptide-pulsed T2D
q targets (pulsed with RNEU420–429 or
NP118–126) and Brefeldin A (GolgiStop, BD Biosciences) for 5 hrs
using a ratio of lymphocytes to targets of 4:1. Absolute numbers of
CD8
+ T cells were determined using samples evaluated for CD8
and Thy1.2 expression only. Cells that were stained for cytokine
expression were first stained for surface CD8 and Thy1.2
expression. Cells were resuspended in FACS buffer (PBS, 5%
FBS, .02% NaAzide) prior to analysis on a FACScalibur (BD
Pharmingen). The percentage of antigen-specific activation was
calculated by subtracting the percentage of cytokine-secreting cells
in NP118–126 -pulsed samples from the percentage of cytokine-
secreting cells in RNEU420–429 -pulsed samples. Absolute numbers
were calculated from total T cell counts specific for each peptide.
The programs Spice and Pestle were used, courtesy of Mario
Roederer of the NIAID Vaccine Research Center, for poly-
cytokine analyses [71].
Treg characterization was assessed using the Foxp3 permeabi-
lization kit (eBioscience) after staining for surface trafficking and
activation markers. Surface markers were stained for 2 hours prior
to extensive washing, fixation/permeabilization, and Foxp3
staining.
Avidity was assessed by dilutional tetramer analyses using the
RNEU420–429/H-2D
q and NP118–126/H-2D
q tetramers. Samples
were stained using tetramers with a beginning concentration of
1.9 mM and dilutions of 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200,
1:500 (950 nM, 380 nM, 190 nM, 95 nM, 38 nM, 19 nM,
9.5 nM, and 3.8 nM respectively) was used to assess T cell avidity
by flow cytometry [11].
Tumor size assessments
Tumors were measured twice weekly, beginning 3 days after
vaccination. Tumor length and width were measured and used to
calculate tumor area. Mice with tumors .1c m
2 were sacrificed
according to Johns Hopkins Animal Care and Use protocols.
Biodistribution studies and in vivo imaging
At various time points after adoptive transfer, mice were
injected i.v. with 20 mg of Thy1.2 monoclonal antibody or control
IgG radiolabeled with 200 mCi indium-111 per mouse. The
High Avidity T Cell Trafficking into Tumors
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[12,72,73]. After 24 hours, lymph nodes, spleens, and tumors were
excised, weighed, and placed in a gamma counter to measure their
radioactivity. For in vivo imaging, mice were treated as described
above. Twenty-four hours after radiolabeled antibody injection the
mice were anesthetized with 3% isofluorane and maintained at 1–
2% with a constant rate of oxygen flow of 1 l/m. Mice were then
imaged by small-animal SPECT/CT (XSPECT system, by
GammaMedica) fitted with a pinhole collimator appropriate for
indium-111 photons.
In vitro suppression assay
CD11c
+ cells were isolated from the vaccine-draining lymph
nodes (VDNs) of FVB/N mice that had been vaccinated 7 days
prior to dissection. Lymph nodes were gently mashed through
40 mM cell strainers and then CD11c
+ cells were positively
selected using CD11c
+ MicroBeads (Miltenyi Biotec). Tregs were
isolated from the spleens and lymph nodes of Foxp3
GFP neu-N mice
that had been vaccinated 7 days prior to isolation. CD4
+ T cells
were isolated using negative selection Dynal CD4
+ T cell isolation
kits (Invitrogen) and then stained for CD25 expression using anti-
CD25-PE (eBioscience) prior to sorting. Foxp3 expression was
indicated by GFP fluorescence and T cells were sorted into either
GFP
+CD25
high or GFP
+CD25
low populations. Control CD4
+ T
cells were isolated from non-vaccinated FVB/N GFP mice using
CD4
+ negative selection. High avidity T cells were isolated from
TCR transgenic mice using CD8
+ T cell negative selection Dynal
kits (Invitrogen). High avidity T cells were then labeled with CFSE
using the CellTrace CFSE Proliferation Kit (Invitrogen). CDllc
+
dendritic cells (DC), Tregs/CD4
+ T cells, and high avidity T cells
were plated at a 1:1:2 ratio. Unstimulated high avidity T cells were
plated as a negative control. CD11c
+ cells were plated with high
avidity cells in a 1:2 ratio and FVB/N-derived CD4
+ T cells,
CD11c
+ cells, and high avidity cells plated at a 1:2:1 ratio, both as
positive controls. Cells were incubated for 3 and 5 days prior to
flow cytometric analysis of CFSE dilution on Thy1.2
+ cells.
In vivo suppression assay
Neu-N/Foxp3
gfp mice were injected with 1610
5 NT2.5 cells
followed by whole cell vaccination 3 days later. Seven days post-
vaccination, splenic CD4
+ T cells were isolated by negative
selection (Invitrogen), and sorted based on FoxP3 and CD25
(Clone 3C7, Biolegend) expression. CD4
+FoxP3
+CD25 high or
low cells (1610
6) were adoptively transferred into FVB/N-
TgN(TIE2GFP)287Sato mice that were vaccinated 1 day later.
Two weeks post-vaccination CD8
+ T cells were negatively isolated
from the FVB/N-TgN(TIE2GFP)287Sato mice and tested for
IFN-c secretion by ICS assay, and the %IFN-c
+ CD8
+ T cells was
evaluated.
Immunohistochemistry (IHC)
One week after receiving a neu-expressing tumor cells, neu-N
mice were treated with Cy, vaccine, and adoptively transferred
high avidity T cells. On day 3 or 5 after treatment, tumors from
neu-N mice were fixed in 10% paraformaldehyde on days 3 and 5
after adoptive transfer. Tumors were imbedded in paraffin and
sectioned by the Johns Hopkins Medical Laboratories, Reference
Histology Lab. Slides were then stained in the Johns Hopkins IHC
laboratory. The anti-mouse CXCL9 antibody (R & D Systems)
was used at a 1:200 dilution with an anti-goat antibody used at a
1:2000 dilution. The Leica-Bond maX system with Bond-max
Software was used, and the epitope retrieval method used was
Leica-Bond ER2.
For immunofluorescence staining of Thy1.2 in the tumors of
treated mice, tumors were frozen in Tissue-Tek OCT (VWR)
prior to preparation of 5 mm sections by the JHMI Pathology core.
Anti-Thy1.2-biotin (BD Pharmingen) and AlexaFluor 488 strep-
tavidin (Invitrogen) were used with standard immunofluorescence
protocols. Blocking was completed with an avidin and biotin
blocking kit (Vector labs). Slides were then mounted using
ProLong Gold anti-fade reagent plus DAPI stain (Molecular
Probes).
Statistical analysis
Statistical analyses were conducted in Microsoft Excel using
either ANOVA analysis or an unpaired, two-tailed, Student’s t-
test, assuming equal population variances. A log-rank test was used
for Kaplan Meier plots.
Supporting Information
Figure S1 Characterization of RNEU420–429-specific,
CD8
+ TCR transgenic mice. Staining CD8
+ T cells from
high and low avidity mice confirms the dominance of the
transgenes. (A) CD8
+ T cells from high avidity mice are .98%
Vb4
+. CD8
+ T cells from an FVB/N control are ,10% Vb4
+.
CD8
+ T cells from low avidity mice stain .95% Vb2
+. CD8
+ T
cells from an FVB/N control are ,17% Vb2
+.( B) Dilutional
tetramer staining confirms avidity of TCR transgenic CD8
+ T
cells. FVB/N mice stain similarly with RNEU420–429/H-2D
q
tetramer (green line) and irrelevant peptide NP118–126/H-2D
q
tetramer (blue line) at 1:5, 1:50, and 1:200 dilutions. Low avidity
TCR transgenic mice show a positive shift in RNEU420–429/H-
2D
q tetramer staining at 1:5 and 1:50 dilutions when compared to
NP118–126/H-2D
q tetramer staining. High avidity TCR transgenic
mice show a strong positive shift of RNEU420–429/H-2D
q tetramer
staining at all dilutions when compared to NP118–126/H-2D
q
tetramer staining. (C) Comparison of CD8, CD3, and Vb
expression on T cells from TCR transgenic mice using antibody
staining. There is no difference in expression of these markers
across mouse lines.
(TIF)
Figure S2 High and low avidity T cells persist longer in
FVB/N than in neu-N mice after adoptive transfer. The
average percent of Thy1.2
+ high or low avidity T cells of the total
CD8
+ T cells in FVB/N or neu-N mice as a measure of cell
persistence at 1, 3, and 5 weeks post-adoptive transfer.
Treatments: Tumor Alone=tumor plus adoptive transfer,
Mock=tumor, 3T3GM mock vaccine, and adoptive transfer,
Vacc=tumor, 3T3neuGM vaccine, and adoptive transfer. Cy
Mock=tumor, Cy, 3T3GM mock vaccine, and adoptive transfer,
Cy Vacc=tumor, Cy, 3T3neuGM vaccine, and adoptive transfer.
High avidity T cell transfer=gray bars; low avidity T cell=white
bars. (A) Adoptive transfer of high or low avidity T cells into
treated FVB/N mice. (B) Adoptive transfer of high or low avidity
T cells into treated neu-N mice. Note different scale on the Y axis.
**=p,.0001.
(TIF)
Figure S3 Polycytokine secreting high and low avidity T
cells are detected following adoptive transfer into
treated FVB/N mice. Lymphocytes were collected from
tumor-draining lymph nodes on day 3 and day 5 and analyzed
for cytokine secretion by ICS as described in the methods. The
absolute # of activated Thy1.2 cells in the tumor-draining nodes
(TDN, Red Bars), vaccine-draining nodes (VDN, Green Bars), and
non-draining nodes (NDN, Blue Bars) on Day 3, 5, and 8 after
High Avidity T Cell Trafficking into Tumors
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TNFa, and IL-2, is shown. (n=3 mice per group). These
experiments were repeated at least three times with similar results.
(A) High avidity T cell transfer with 3T3GM Mock (Left) or
3T3neuGM vaccine (Right). (B) High avidity T cell transfer with
Cy plus 3T3GM Mock (Left) or 3T3neuGM vaccine (Right). (C)
Low avidity T cell transfer with Cy plus 3T3GM Mock (Left) or
3T3neuGM vaccine (Right). Polyclonal cytokine expression was
not detected at high levels in low avidity T cells transferred into
FVB/N mice treated with vaccine or mock vaccine without Cy
(data not shown).
(TIF)
Figure S4 Neu-N mouse tumors produce higher levels of
CXCL9 following treatment with Cy and adoptively
transferred high avidity T cells. CXCL9 staining of neu-
expressing tumors on day 3 (Left Panels) or 5 (Right Panels) after
treatment as described in the Methods, Top panels: High avidity T
cell transfer+3T3neuGM vaccine. Middle panels: Cy+3T3neuGM
vaccine. Lower panels: High avidity T cell transfer+Cy+3T3-
neuGM vaccine.
(TIF)
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